Qsymia UK: Medical Information and Licensing Status
People searching for Qsymia uk often want to understand what this medicine contains, how it is used for weight management and whether it is licensed in the United Kingdom. Alluvi Healthcare encourages readers to check reliable medical and regulatory information before making decisions about medicines, particularly products that do not have UK marketing authorisation.
What Is Qsymia?
Qsymia is a prescription medicine authorised in the United States for chronic weight management in eligible patients. It combines two active ingredients: phentermine and topiramate in an extended-release capsule.
Phentermine is a sympathomimetic medicine that acts as an appetite suppressant. Topiramate is a medicine originally developed for other medical uses that can also influence appetite and food intake. The combination has been studied for its effects on body weight when used alongside a reduced-calorie diet and increased physical activity.
Is Qsymia Available or Licensed in the UK?
Qsymia does not have a UK marketing authorisation and is not a routinely licensed UK weight-management medicine. Its US approval should not be interpreted as UK approval or as evidence that a Qsymia-branded product can be routinely prescribed or supplied by a UK pharmacy.
People researching Qsymia uk should distinguish between a medicine being authorised in another country and having a marketing authorisation in the UK. Medicines supplied outside their authorised conditions may be subject to specific legal and regulatory requirements. The status of a particular product should be checked with the Medicines and Healthcare products Regulatory Agency (MHRA).
For official UK medicine information, consult the MHRA Products database.
How Does the Phentermine and Topiramate Combination Work?
Qsymia combines two ingredients that act through different pathways:
- Phentermine: A sympathomimetic amine that influences central nervous system activity and can reduce appetite.
- Topiramate: An anticonvulsant medicine with several neurological effects. Its influence on appetite and food intake is part of the rationale for its use in this combination.
The US-authorised product is intended to be used alongside dietary changes and increased physical activity. Its effects, limitations and suitability depend on the individual and require medical oversight.
Qsymia and Its US Regulatory Approval
Qsymia received approval from the United States Food and Drug Administration (FDA) in 2012. In the United States, it is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in certain eligible adults. The US label also includes an indication for certain paediatric patients.
These US indications do not establish authorisation in the United Kingdom. Regulatory approval is country-specific, and patients should not assume that the conditions of use in one country apply elsewhere.
Read the official US Qsymia prescribing information for the approved US label and safety details.
Possible Qsymia Side Effects and Safety Considerations
The US prescribing information identifies several possible adverse effects and important safety warnings. Reported effects include:
- Dry mouth
- Constipation
- Tingling sensations in the hands or feet
- Altered taste
- Insomnia or sleep difficulties
- Dizziness
- Changes in heart rate
- Difficulty with concentration, memory or attention
More serious warnings in the US prescribing information include potential harm to an unborn baby, increased heart rate, mood or behavioural changes, eye problems including acute angle-closure glaucoma, metabolic acidosis and kidney-related complications.
Qsymia is contraindicated in pregnancy, glaucoma, hyperthyroidism and certain circumstances involving monoamine oxidase inhibitors. The full prescribing information contains further warnings and contraindications. This summary is not a substitute for the official label or professional medical advice.
Why Is UK Licensing Important?
A UK marketing authorisation involves regulatory assessment of a medicine’s quality, safety and efficacy for its proposed use. A product authorised by the FDA in the United States does not automatically receive approval from the MHRA.
Before relying on claims about a medicine’s UK status, check official regulatory information and seek advice from an appropriately qualified healthcare professional. The MHRA provides a searchable database of UK medicine product information and authorisation details.
Weight Management Information
There are different approaches to weight management, including nutritional support, physical activity, behavioural interventions and medicines that have been authorised for specific uses. The suitability of any treatment depends on an individual’s health, medical history and clinical assessment.
Alluvi Healthcare Weight Loss is the relevant site category label. The presence of a product in a category does not establish that the product is licensed, suitable for treatment or available for lawful supply in the UK.
Qsymia UK: Frequently Asked Questions
Is Qsymia licensed in the UK?
Qsymia does not have a UK marketing authorisation. Its US approval does not make it a routinely licensed UK medicine.
What ingredients does Qsymia contain?
Qsymia contains phentermine and topiramate in an extended-release capsule formulation.
What is Qsymia approved for in the United States?
The FDA-authorised product is used alongside a reduced-calorie diet and increased physical activity for chronic weight management in specified eligible patient groups.
Can Qsymia cause side effects?
Yes. The US prescribing information describes effects such as dry mouth, constipation, tingling sensations, altered taste, sleep difficulties and dizziness, as well as more serious warnings and precautions.
Does US approval mean Qsymia is approved in the UK?
No. US FDA approval and UK marketing authorisation are separate regulatory decisions. Always check the MHRA database for UK medicine authorisation information.
Where can I find reliable information about Qsymia?
The US FDA and DailyMed publish official prescribing information. The MHRA provides UK medicine product and regulatory information.
Further Information About Alluvi Healthcare
To learn more about the organisation, visit About Alluvi Healthcare. For general enquiries, use the Alluvi Healthcare contact page.
Additional authoritative information:
- MHRA – UK Medicines and Healthcare Products Database
- DailyMed – Qsymia Official Drug Label
- NICE – Phentermine with Topiramate: Assessment Scope
Important information: This page is for general educational purposes only. It does not recommend, advertise or offer Qsymia for supply in the United Kingdom. Qsymia does not have a UK marketing authorisation. This information is not a substitute for medical advice, diagnosis or treatment.




